Cause-specific effects of radiotherapy and lymphadenectomy in stage I-II endometrial cancer: A population-based study

Journal of the National Cancer Institute

Volumn 105, Issue 21, 2013, Pages 1656-1666

  Mell, Loren K ^a   Carmona, Ruben ^a   Gulaya, Sachin ^a   Lu, Tina ^a   Wu, John ^a   Saenz, Cheryl C ^b   Vaida, Florin ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND CANCER; STATISTICAL ANALYSIS; STRATIFICATION;

ADULT; AGED; CONFOUNDING FACTORS (EPIDEMIOLOGY); ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; LYMPH NODE EXCISION; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SEER PROGRAM; UNITED STATES;

EID: 84890545299     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt279     Document Type: Article

References (24)

1. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241.
2. Lee CM, Szabo A, Shrieve DC, et al. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA. 2006;295(4):389-397.
3. Chino JP, Jones E, Berchuck A, et al. The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. Int J Radiat Oncol Biol Phys. 2012;82(5):1872-1879.
4. Todo Y, Kato H, Kaneuchi M, et al. Survival effect of para-Aortic lymphadenectomy in endometrial cancer (SEPAL study): A retrospective cohort analysis. Lancet. 2010;375(9721):1165-1172.
5. Kim HS, Suh DH, Kim MK, et al. Systematic lymphadenectomy for survival in patients with endometrial cancer: A meta-Analysis. Jpn J Clin Oncol. 2012;42(5):405-412.
6. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744-751.
7. Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e631-e638.
8. Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and metaanalysis. Lancet. 2009;373(9658):137-146.
9. ASTEC study group, Kitchener H, Swart AM, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet. 2009;373(9658):125-136.
10. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707-1716.
11. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev. 2012;4(4):CD003916.
12. May K, Bryant A, Dickinson HO, et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2010; (1):CD007585.
13. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer: An updated Cochrane systematic review and metaanalysis. J Natl Cancer Inst. 2012;104(21):1625-1634.
14. Ward KK, Shah NR, Saenz CC, et al. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012;126(2):176-179.
15. Smith DC, Macdonald OK, Lee CM, et al. Survival impact of lymph node dissection in endometrial adenocarcinoma: A surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer. 2008;18(2):255-261.
16. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-2008). http://www.seer.cancer.gov. Accessed August 22, 2012.
17. Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;34(2):187-220.
18. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc. 1993; 88:400-409.
19. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
20. Prentice RL, Kalbfleisch JD, Peterson AV Jr, et al. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541-554.
21. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
22. Ferreira-González I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 2007;334(7597):786.
23. Mell LK, Lau SK, Rose BS, et al. Reporting of cause-specific treatment effects in cancer clinical trials with competing risks: A systematic review. Contemp Clin Trials 2012;33(5):920-924.
24. Lund JL, Harlan LC, Yabroff KR, et al. Should cause of death from the death certificate be used to examine cancer-specific survival? A study of patients with distant stage disease. Cancer Invest. 2010;28(7):758-764.